Nothing Special   »   [go: up one dir, main page]

WO2007107706A3 - Dimers of heterocyclic compounds for the treatment of copd - Google Patents

Dimers of heterocyclic compounds for the treatment of copd Download PDF

Info

Publication number
WO2007107706A3
WO2007107706A3 PCT/GB2007/000919 GB2007000919W WO2007107706A3 WO 2007107706 A3 WO2007107706 A3 WO 2007107706A3 GB 2007000919 W GB2007000919 W GB 2007000919W WO 2007107706 A3 WO2007107706 A3 WO 2007107706A3
Authority
WO
WIPO (PCT)
Prior art keywords
dimers
treatment
copd
heterocyclic compounds
compounds
Prior art date
Application number
PCT/GB2007/000919
Other languages
French (fr)
Other versions
WO2007107706A2 (en
Inventor
Harry Finch
Christine Edwards
Nicholas Charles Ray
Original Assignee
Argenta Discovery Ltd
Harry Finch
Christine Edwards
Nicholas Charles Ray
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argenta Discovery Ltd, Harry Finch, Christine Edwards, Nicholas Charles Ray filed Critical Argenta Discovery Ltd
Publication of WO2007107706A2 publication Critical patent/WO2007107706A2/en
Publication of WO2007107706A3 publication Critical patent/WO2007107706A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Covalent conjugates of two or more compounds, each having a structure as defined in any of WO2004/043924, WO2005/021509, WO2005/021512, WO2005/026123, WO2005/026124, WO2006/098683 and WO2006/098684, are inhibitors of human neutrophil elastase, useful in treatment of, for example, chronic obstructive pulmonary disease. Dimers of formula (IA) or (IB): wherein LINKER and the variable substituents are particular types of such multimers.
PCT/GB2007/000919 2006-03-17 2007-03-16 Dimers of heterocyclic compounds for the treatment of copd WO2007107706A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0605469.6 2006-03-17
GBGB0605469.6A GB0605469D0 (en) 2006-03-17 2006-03-17 Multimers of heterocyclic compounds and their use

Publications (2)

Publication Number Publication Date
WO2007107706A2 WO2007107706A2 (en) 2007-09-27
WO2007107706A3 true WO2007107706A3 (en) 2008-10-09

Family

ID=36293016

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/000919 WO2007107706A2 (en) 2006-03-17 2007-03-16 Dimers of heterocyclic compounds for the treatment of copd

Country Status (2)

Country Link
GB (1) GB0605469D0 (en)
WO (1) WO2007107706A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302486D0 (en) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
US20110003858A1 (en) * 2006-09-04 2011-01-06 Bergstroem Lena Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
WO2009037413A1 (en) * 2007-09-19 2009-03-26 Argenta Discovery Limited Dimers of 5- [ (4-cyanophenyl) sulfinyl] -6-methyl-2-oxo-1- [3- (trifluoromethyl)phenyl] -1,2-dihydropyridine-3-carboxamide as inhibitors of human neutrophil elastase for treating respiratory diseases
KR20100096131A (en) 2007-11-06 2010-09-01 아스트라제네카 아베 Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
MX2012003644A (en) * 2009-10-02 2012-04-30 Astrazeneca Ab 2-pyridone compounds used as inhibitors of neutrophil elastase.
CA2915633A1 (en) 2013-07-02 2015-01-08 The California Institute For Biomedical Research Compounds for treatment of cystic fibrosis
US9221807B2 (en) * 2014-02-21 2015-12-29 Boehringer Ingelheim International Gmbh Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity
WO2015179823A2 (en) * 2014-05-23 2015-11-26 The California Institute For Biomedical Research Lung localized inhibitors of alpha(v)beta 6
US9487528B2 (en) * 2014-06-09 2016-11-08 Chiesi Farmaceutici S.P.A. Compounds
CA2951734A1 (en) * 2014-06-12 2015-12-17 Chiesi Farmaceutici S.P.A. Novel compounds
WO2015200349A2 (en) * 2014-06-24 2015-12-30 The California Institute For Biomedical Research Elastase inhibitors
WO2016112120A1 (en) * 2015-01-07 2016-07-14 The California Institute For Biomedical Research Compounds for treatment of cystic fibrosis
WO2017207430A1 (en) * 2016-05-31 2017-12-07 Chiesi Farmaceutici S.P.A. Imidazolone compounds as human neutrophil elastase inhibitors
KR20220079527A (en) 2019-09-17 2022-06-13 메레오 바이오파마 4 리미티드 Alberestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome, and graft-versus-host disease
AU2021256835A1 (en) 2020-04-16 2022-10-13 Mereo Biopharma 4 Limited Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
WO2023067103A1 (en) 2021-10-20 2023-04-27 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043924A1 (en) * 2002-11-12 2004-05-27 Astrazeneca Ab 2-pyridone derivatives as inhibitors of neutrophile elastase
WO2005021512A1 (en) * 2003-08-28 2005-03-10 Astrazeneca Ab Quinoxaline derivatives as neutrophil elastase inhibitors and their use
WO2005021509A1 (en) * 2003-08-28 2005-03-10 Astrazeneca Ab Quinoline derivatives as neutrophil elastase inhibitors and their use
WO2005026123A1 (en) * 2003-09-18 2005-03-24 Astrazeneca Ab 2-pyridone derivatives as neutrophil elastase inhibitors and their use
WO2005026124A1 (en) * 2003-09-18 2005-03-24 Astrazeneca Ab 2-pyridone derivatives as netrophil elastase inhibitors and their use
WO2008030158A1 (en) * 2006-09-04 2008-03-13 Astrazeneca Ab Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043924A1 (en) * 2002-11-12 2004-05-27 Astrazeneca Ab 2-pyridone derivatives as inhibitors of neutrophile elastase
WO2005021512A1 (en) * 2003-08-28 2005-03-10 Astrazeneca Ab Quinoxaline derivatives as neutrophil elastase inhibitors and their use
WO2005021509A1 (en) * 2003-08-28 2005-03-10 Astrazeneca Ab Quinoline derivatives as neutrophil elastase inhibitors and their use
WO2005026123A1 (en) * 2003-09-18 2005-03-24 Astrazeneca Ab 2-pyridone derivatives as neutrophil elastase inhibitors and their use
WO2005026124A1 (en) * 2003-09-18 2005-03-24 Astrazeneca Ab 2-pyridone derivatives as netrophil elastase inhibitors and their use
WO2008030158A1 (en) * 2006-09-04 2008-03-13 Astrazeneca Ab Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HAN YI FAN ET AL: "Dual-site binding of bivalent 4-aminopyridine- and 4-aminoquinoline-based AChE inhibitors: contribution of the hydrophobic alkylene tether to monomer and dimer affinities", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 7, no. 11, 1 January 1999 (1999-01-01), pages 2569 - 2575, XP002365936, ISSN: 0968-0896 *

Also Published As

Publication number Publication date
WO2007107706A2 (en) 2007-09-27
GB0605469D0 (en) 2006-04-26

Similar Documents

Publication Publication Date Title
WO2007107706A3 (en) Dimers of heterocyclic compounds for the treatment of copd
IL250847A0 (en) 5-substituted quinazolinone derivatives as antitumor agents
WO2007021937A3 (en) Unsaturated heterocyclic derivatives
WO2007087395A3 (en) UNSATURATED mTOR INHIBITORS
WO2008024978A3 (en) Tetrahydroindolone and tetrahydroindazolone derivatives
EP2057158B8 (en) Triazole derivatives as kinase inhibitors
WO2009036092A3 (en) Mitochondria-targeted anti-tumour agents
ATE447568T1 (en) NEW PYRINE DERIVATIVES
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
PT2044036E (en) [4,5`]bipyrimidinyl-6,4`-diamine derivatives as protein kinase inhbitors
WO2010038086A8 (en) P38 map kinase inhibitors
WO2009155121A3 (en) Inhibitors of pi3 kinase
WO2008048867A3 (en) Bicyclic heteroaromatic compounds
WO2007015017A3 (en) Novel polyquinoline derivatives and the therapeutic use thereof
WO2007135527A3 (en) Benzimidazolyl compounds
WO2009087098A3 (en) Quinoline derivatives and their use as fungicides
WO2010058032A3 (en) Substituted pyrimidines for the treatment of diseases such as cancer
WO2007115620A3 (en) Novel cyclobutyl compounds as kinase inhibitors
HK1137990A1 (en) Thienyl-containing glycopyranosyl derivatives as antidiabetics
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
MX2009003081A (en) Pyrrole derivatives useful for the treatment of cytokine-mediated diseases.
WO2007097981A3 (en) Alpha carbolines and uses thereof
WO2007034279A3 (en) C3a antagonists and pharmaceutical compositions thereof
WO2008008700A3 (en) Substituted cyclopentane derivatives as therapeutic agents
WO2007144057A3 (en) Antimicrobial carbon

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07712911

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07712911

Country of ref document: EP

Kind code of ref document: A2